Diseases & Illness |

PML News

Tysabri Closer to Approval in Europe

RSS News Feeds
Disease from Products
PML
 All RSS Feeds

At a glance:

The controversial Multiple Sclerosis drug Tysabri is a step closer to approval in the European Union. 
 
An advisory committee has recommended its use in certain cases of MS, as a stand-alone therapy (that is, not in combination with other drugs). 
 
No further cases of the deadly brain condition PML have been detected in Tysabri users. This complication is what led to Tysabri being withdrawn from the market last year. 
 
A decision in the US is expected this summer.

MS drug Tysabri closer to EU launch

United Press International - 4/28/2006 3:03 PM

CAMBRIDGE, Mass., April 28 (UPI) -- Biogen Idec and Elan said their multiple-sclerosis drug Tysabri has been recommended for approval in Europe.
 
As the companies await the drug's return to the U.S. market this year, they announced Friday that Europe's Committee for Medicinal Products for Human Use has issued an opinion that Tysabri should be approved for relapsing-remitting MS to delay the progression of disability and reduce the frequency of relapses.
 
· Read The Full PML Article From United Press International -->

· Read All PML News Stories -->

Comments On PML News Articles:


No Current Comments
Posted by Admin on 3/20/2006

There are no current comments. Why not post one?

Leave a Comment:

Once you click the 'Save Comment' button, you will receive a verification email from our website. Be sure to change any spam settings to allow webmaster@lawsuitsearch.com as a trusted sender.
 
If you are already a member, you can Sign In Here.
 
You can create your own FREE user account that you can use to participate in our message boards, blogs, newsletters and other community activities such as this one. To get your FREE user account, click here.

Email Address:

Your Name:

Message Title:

Message: